| Followers | 202 |
| Posts | 25627 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Thursday, December 22, 2022 7:27:14 AM
You can’t patent concepts.
It was a duly finished product for creating any dendritic cell based medical product. However, NWBO needs to replace their existing production, which they used for their trial, with an automated process, and that’s not just one machine, it’s like any automated manufacturing process, you have machines working together in the process, with people, to create a finished, commercial product. There is no indication of any problems. So why do you ask? It’s not a computer or something. You know this right? Creating a manufacturing process like this is a highly technical engineering task not just putting things together but maintains purity and sterility and all measures for a proper effective final product that reaches the plant with live inputs, and then is stored and delivered in a specific schedule to disparate places in pure form. The entire process needs to be robust enough to meet the challenges of scaling to commercial levels of production including potentially up to and beyond the demand for the current standard of care.
It was a duly finished product for creating any dendritic cell based medical product. However, NWBO needs to replace their existing production, which they used for their trial, with an automated process, and that’s not just one machine, it’s like any automated manufacturing process, you have machines working together in the process, with people, to create a finished, commercial product. There is no indication of any problems. So why do you ask? It’s not a computer or something. You know this right? Creating a manufacturing process like this is a highly technical engineering task not just putting things together but maintains purity and sterility and all measures for a proper effective final product that reaches the plant with live inputs, and then is stored and delivered in a specific schedule to disparate places in pure form. The entire process needs to be robust enough to meet the challenges of scaling to commercial levels of production including potentially up to and beyond the demand for the current standard of care.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
